CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.05 to $0.29
• 52-Week Range: $0.05 to $12.80
• Volume: 19.79 million shs
• Average Volume: 22.09 million shs
• Market Capitalization: $9.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CERO Stock Analysis - Frequently Asked Questions

How have CERO shares performed this year?

CERo Therapeutics' stock was trading at $4.78 on January 1st, 2024. Since then, CERO stock has decreased by 98.7% and is now trading at $0.06.
View the best growth stocks for 2024 here.

How do I buy shares of CERo Therapeutics?

Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CERo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI).

Company Calendar

• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CUSIP: N/A
• CIK: 1870404
• Web: www.cero.bio
• Phone: 215-731-9450
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -108.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.39
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.59) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 150,313,000
• Free Float: 123,257,000
• Market Cap: $9.36 million
• Optionable: N/A
• Beta: 0.25